Get the Stockscreener App
0.3298
1.70%
-0.0057
Scilex Holding Company stock is traded at $0.3298, with a volume of 789.60K.
It is down -1.70% in the last 24 hours and down -22.03% over the past month.
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for the relief of pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.
See More
Previous Close:
$0.3355
Open:
$0.34
24h Volume:
789.60K
Relative Volume:
0.52
Market Cap:
$60.43M
Revenue:
$46.74M
Net Income/Loss:
$-114.33M
P/E Ratio:
-0.2557
EPS:
-1.29
Net Cash Flow:
$-21.04M
1W Performance:
-6.84%
1M Performance:
-22.03%
6M Performance:
-73.40%
1Y Performance:
-81.37%
1-Day Range:
$0.3206
$0.342
1-Week Range:
$0.3206
$0.3637
52-Week Range:
$0.3206
$2.63
Scilex Holding Company Stock (SCLX) Company Profile
Name
Scilex Holding Company
Sector
Industry
Phone
(650) 516-4310
Address
960 SAN ANTONIO ROAD, PALO ALTO
Compare SCLX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SCLX
Scilex Holding Company
|
0.3298 | 60.43M | 46.74M | -114.33M | -21.04M | -1.29 |
|
LLY
Lilly Eli Co
|
873.68 | 830.35B | 45.04B | 10.59B | 414.30M | 11.71 |
|
NVO
Novo Nordisk Adr
|
88.08 | 390.99B | 42.09B | 14.65B | 10.11B | 3.2833 |
|
ABBV
Abbvie Inc
|
202.08 | 356.74B | 56.33B | 4.28B | 17.83B | 2.40 |
|
JNJ
Johnson Johnson
|
162.30 | 344.63B | 88.82B | 14.07B | 18.06B | 5.79 |
|
MRK
Merck Co Inc
|
89.50 | 251.88B | 64.17B | 17.12B | 14.84B | 6.7297 |
Scilex Holding Company Stock (SCLX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-27-25 | Initiated | D. Boral Capital | Buy |
| Oct-16-24 | Initiated | Alliance Global Partners | Buy |
| Jun-13-24 | Initiated | Rodman & Renshaw | Buy |
| Oct-16-23 | Initiated | B. Riley Securities | Buy |
| Oct-13-23 | Initiated | B. Riley Securities | Buy |
| Oct-09-23 | Initiated | H.C. Wainwright | Buy |
View All
Scilex Holding Company Stock (SCLX) Latest News
Scilex (NASDAQ:SCLX) Stock Price Down 1.7% – Time to Sell? - Defense World
Scilex seeks FDA nod for ELYXYB in acute pain management - MSN
Denali Capital Acquisition Corp. Announces Extension of Deadline to Complete Business Combination - The Manila Times
Merger Deadline Extended: Denali Capital's Strategic Move Backed by Interest-Free $180K Funding - StockTitan
The growth track for Scilex Holding Company (SCLX) has changed recently - SETE News
Analytical Lens: Exploring Scilex Holding Company (SCLX)’s Financial Story Through Ratios - The Dwinnex
D. Boral Capital analysts initates a Buy rating for Scilex Holding Company (SCLX) - Knox Daily
Scilex Holding Company [NASDAQ: SCLX] Sees Decrease in Stock Value - Knox Daily
A company insider recently sold 23,343 shares of Newell Brands Inc [NWL]. Should You Sale? - Knox Daily
Sciatica Treatment Market to Reach at a CAGR 9.7% During - openPR
A company insider recently sold 187,500 shares of Solid Power Inc [SLDP]. Should You Sale? - Knox Daily
SCLX’s Stock Market Adventure: -6.00% YTD Growth Amidst Volatility - The InvestChronicle
Investing in Scilex Holding Company (SCLX) might be an excellent idea, but the stock is currently overvalued/undervalued – US Post News - US Post News
Scilex Dividend Stock lock-up extended to April 14 - MSN
Scilex (NASDAQ:SCLXW) Stock Price Down 4.8% – What’s Next? - Defense World
Investor’s Delight: Scilex Holding Company (SCLX) Closes Weak at 0.41, Down -6.39 - The Dwinnex
UBS Upgrades Rocket Companies Inc (RKT) to a Neutral from a Sell - Knox Daily
Scilex Holding Company (SCLX) rating initates by D. Boral Capital - Knox Daily
Scilex Dividend Stock lock-up extended to April 14 By Investing.com - Investing.com Australia
Scilex Holding Company Announces that the U.S. Bankruptcy Court has Extended the Lockup Period on Shares of Scilex Dividend Stock Previously Distributed by Sorrento to its Stockholders as a Dividend to April 14, 2025 - The Manila Times
Scilex Holding Company Announces that the U.S. Bankruptcy - GlobeNewswire
Court Mandates 15-Month Extension on Scilex Dividend Stock Trading Restrictions - StockTitan
SCLX stock touches 52-week low at $0.38 amid market challenges - Investing.com
Scilex (NASDAQ:SCLX) Coverage Initiated by Analysts at D. Boral Capital - Defense World
D. Boral Capital Initiates Coverage of Scilex Holding (SCLX) with Buy Recommendation - MSN
This Vital Farms Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
Holding Company Shares Rally Following Board Of Directors Commentary - MSN
Scilex Holding Faces Financial Strain Amid Form S-3 Ineligibility Crisis - TipRanks
SCLX Beats on Earnings as Product Line Expands - MSN
Scilex FDA submission for ELYXYB acute pain treatment acknowledged - MSN
Scilex Holding Company Announces that the U.S. FDA Has Acknowledged the Submission of Our Supplemental New Drug Application for ELYXYB® in Acute Pain Indication - The Manila Times
Scilex Amends Note Maturity and Cash Sweep Terms - TipRanks
Nio Inc ADR (NIO-N) QuotePress Release - The Globe and Mail
Scilex Holding Company Announces that It Regains Nasdaq Compliance Under Listing Rule 5250(c)(1) - The Manila Times
Toyota Motor Corp Ltd Ord ADR (TM-N) QuotePress Release - The Globe and Mail
Scilex Holding Company Announces Extension of the Maturity Date of its Secured Promissory Note Issued to Oramed Pharmaceuticals Inc. to December 31, 2025 - The Manila Times
Scilex Holding Company Announces that Its Note Holders Intend to Participate in the Funding and Licensing of Gloperba® Ex-U.S. Commercialization Rights from Romeg Therapeutics, LLC - The Manila Times
Scilex Holding Company Announces that It Will Be Filing Today of a Supplemental New Drug Application with the FDA for ELYXYB® in Acute Pain Indication - The Manila Times
Scilex Holding Company Announces Filing of its Quarterly Report on Form 10-Q for the Quarter Ended September 30, 2024 - The Manila Times
Nvidia Corp (NVDA-Q) QuotePress Release - The Globe and Mail
Microstrategy Cl A (MSTR-Q) QuotePress Release - The Globe and Mail
Scilex Holding Company Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Scilex Holding Company (SCLX) reports earnings - Quartz
Jane Street Group LLC Trims Position in Scilex Holding (NASDAQ:SCLX) - Defense World
Scilex Holding Company Amends its License Agreement with Romeg Therapeutics, LLC, For the Worldwide Rights to Commercialize Gloperba®, an FDA-Approved Prophylactic Treatment for Painful Gout Flares in Adults - Yahoo Finance
Scilex Holding Company Expands Global Potential for Gloperba® with License Agreement Amendment for Ex-US Commercialization - Nasdaq
Scilex Holding Company Announces Pain Medicine News Published Retrospective Claims Data on ZTlido® vs. Lidocaine 5% Patch - The Manila Times
Scilex Holding Company Announces Pain Medicine News - GlobeNewswire
Scilex (NASDAQ:SCLXW) Trading Up 22.5% – Here’s Why - Defense World
Scilex Holding Company Stock (SCLX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Scilex Holding Company Stock (SCLX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Ji Henry | Executive Chairperson |
Oct 31 '24 |
Buy |
0.94 |
8,888 |
8,351 |
320,161 |
| SHAH JAISIM | See Remarks |
Oct 29 '24 |
Buy |
0.99 |
32,000 |
31,670 |
109,333 |
| Followwill Dorman | Director |
Oct 18 '24 |
Buy |
0.99 |
1,000 |
990 |
2,300 |
| Chun Jay | Director |
Oct 18 '24 |
Buy |
0.95 |
5,000 |
4,750 |
112,500 |
| Wu Yue Alexander | Director |
Oct 17 '24 |
Buy |
0.95 |
20,000 |
18,992 |
25,000 |
| Lemus David | Director |
Oct 17 '24 |
Buy |
0.90 |
2,000 |
1,800 |
2,000 |
| Ji Henry | Executive Chairperson |
Oct 17 '24 |
Buy |
0.97 |
10,000 |
9,710 |
60,070 |
| SHAH JAISIM | See Remarks |
Oct 16 '24 |
Buy |
0.99 |
30,000 |
29,751 |
77,333 |
| Ma Stephen Hoi | Chief Financial Officer |
Oct 16 '24 |
Buy |
0.97 |
6,700 |
6,499 |
22,840 |
| Followwill Dorman | Director |
Jun 26 '24 |
Option Exercise |
1.37 |
1,000 |
1,370 |
1,300 |
0.61%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):